TRANSDERM SCOP Rx
Generic Name and Formulations:
Scopolamine 1.5mg (delivers approximately 1mg over 3 days); transdermal patch.
Novartis Consumer Health
Indications for TRANSDERM SCOP:
Prevention of motion sickness and post-op nausea and vomiting.
Apply to dry skin behind ear; do not cut patch. Motion sickness: 1 patch at least 4 hours before travel; remove after 72 hours. Post-op: 1 patch evening before surgery; for cesarean section: 1 patch 1 hour before surgery. Remove 24 hours after surgery.
Narrow angle glaucoma. Allergy to belladonna alkaloids.
Wash hands and skin after use; avoid eyes. GI or urinary tract obstruction. Hepatic, renal, or metabolic dysfunction. Seizure. Psychosis. Elderly. Pregnancy (Cat.C). Nursing mothers.
Alcohol, other CNS depressants potentiate CNS depression. Additive anticholinergic effects with other anticholinergics, antihistamines (e.g., meclizine), antidepressants. May affect absorption of other drugs.
Dry mouth, drowsiness, blurred vision, disorientation, confusion, difficult urination; withdrawal symptoms may occur if used for >3 days.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|